[
  {
    "ts": null,
    "headline": "Does Bristol-Myers Squibb’s 22% Drop in 2024 Suggest an Opportunity for Investors?",
    "summary": "If you are weighing your next move with Bristol-Myers Squibb, you are definitely not alone. The stock has been on a rollercoaster, and plenty of investors are scratching their heads right now, asking whether the tough run offers a rare opportunity or signals deeper risks. Just in the past week, shares nudged up 1.8%, offering a glimmer of optimism. Yet, zoom out, and the scars of a challenging year are clear, with Bristol-Myers Squibb still down nearly 22% for 2024 and more than 30% over...",
    "url": "https://finnhub.io/api/news?id=7d2d20732f8480272b4e58308022d2f4e755c7a3b87fa03334b3509e616bd7e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761243481,
      "headline": "Does Bristol-Myers Squibb’s 22% Drop in 2024 Suggest an Opportunity for Investors?",
      "id": 137198407,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "If you are weighing your next move with Bristol-Myers Squibb, you are definitely not alone. The stock has been on a rollercoaster, and plenty of investors are scratching their heads right now, asking whether the tough run offers a rare opportunity or signals deeper risks. Just in the past week, shares nudged up 1.8%, offering a glimmer of optimism. Yet, zoom out, and the scars of a challenging year are clear, with Bristol-Myers Squibb still down nearly 22% for 2024 and more than 30% over...",
      "url": "https://finnhub.io/api/news?id=7d2d20732f8480272b4e58308022d2f4e755c7a3b87fa03334b3509e616bd7e3"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: This High FCF Yield Is The Best Value In Healthcare",
    "summary": "Discover why Bristol-Myers Squibb (BMY) is a strong buy in 2024âundervalued, high dividend, and robust strategies for long-term investors. Click to read.",
    "url": "https://finnhub.io/api/news?id=d729dd526bd8fa1da7cf05a48e4a55082c59078e52c42e526b717689b2af5e36",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761240018,
      "headline": "Bristol-Myers Squibb: This High FCF Yield Is The Best Value In Healthcare",
      "id": 137198983,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover why Bristol-Myers Squibb (BMY) is a strong buy in 2024âundervalued, high dividend, and robust strategies for long-term investors. Click to read.",
      "url": "https://finnhub.io/api/news?id=d729dd526bd8fa1da7cf05a48e4a55082c59078e52c42e526b717689b2af5e36"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=f30e58dd1a08bf96d3a604b5b59cd6fe60154d6576916a23963f300a24b71f04",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761237660,
      "headline": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
      "id": 137253843,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=f30e58dd1a08bf96d3a604b5b59cd6fe60154d6576916a23963f300a24b71f04"
    }
  },
  {
    "ts": null,
    "headline": "Analyst Says Bristol-Myers Squibb (BMY) Among the Best ‘Deep Value’ Stocks to Buy",
    "summary": "We recently published Top 10 Trending Stocks Everyone’s Watching in Q4. Bristol-Myers Squibb Company (NYSE:BMY) is one of the trending stocks everyone’s watching. Morningstar’s Dave Sekera said in a recent program on Schwab Network that BMY is one of the top deep value stocks today. The analyst mentioned the stock’s dividend yield and valuation: “Well, […]",
    "url": "https://finnhub.io/api/news?id=8675e3e11e2eed4145406aa032fc5dfd4a43e10151d7e69703b13f96d87fde92",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761234439,
      "headline": "Analyst Says Bristol-Myers Squibb (BMY) Among the Best ‘Deep Value’ Stocks to Buy",
      "id": 137198408,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently published Top 10 Trending Stocks Everyone’s Watching in Q4. Bristol-Myers Squibb Company (NYSE:BMY) is one of the trending stocks everyone’s watching. Morningstar’s Dave Sekera said in a recent program on Schwab Network that BMY is one of the top deep value stocks today. The analyst mentioned the stock’s dividend yield and valuation: “Well, […]",
      "url": "https://finnhub.io/api/news?id=8675e3e11e2eed4145406aa032fc5dfd4a43e10151d7e69703b13f96d87fde92"
    }
  },
  {
    "ts": null,
    "headline": "Radiopharmaceuticals Market to Reach US$ 13.4 Billion by 2033 | Astute Analytica",
    "summary": "Surging multibillion dollar acquisitions and a pipeline of innovative therapies define the current landscape. A strong focus on oncology theranostics, supported by new regulatory approvals, is rapidly advancing personalized cancer treatment possibilities.Chicago, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The global radiopharmaceuticals market was valued at US$ 6.8 billion in 2024 and is expected to reach US$ 13.4 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025–2033. The radiop",
    "url": "https://finnhub.io/api/news?id=258ee801c9efed665132d97319bf8eff446230eb17b25f9d8eed1847a91003b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761233400,
      "headline": "Radiopharmaceuticals Market to Reach US$ 13.4 Billion by 2033 | Astute Analytica",
      "id": 137197693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Surging multibillion dollar acquisitions and a pipeline of innovative therapies define the current landscape. A strong focus on oncology theranostics, supported by new regulatory approvals, is rapidly advancing personalized cancer treatment possibilities.Chicago, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The global radiopharmaceuticals market was valued at US$ 6.8 billion in 2024 and is expected to reach US$ 13.4 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025–2033. The radiop",
      "url": "https://finnhub.io/api/news?id=258ee801c9efed665132d97319bf8eff446230eb17b25f9d8eed1847a91003b7"
    }
  },
  {
    "ts": null,
    "headline": "Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for",
    "summary": "Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=96ec5b3fadff62e81b71b000f8c8e9ab986f16637d166a5e5b0ab771b2119379",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761228012,
      "headline": "Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for",
      "id": 137198410,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=96ec5b3fadff62e81b71b000f8c8e9ab986f16637d166a5e5b0ab771b2119379"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=a0575abd8e09c43340712d4e957e08a3ff86412fa7dc052627f1d5ee69a54873",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761224403,
      "headline": "Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 137198411,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=a0575abd8e09c43340712d4e957e08a3ff86412fa7dc052627f1d5ee69a54873"
    }
  },
  {
    "ts": null,
    "headline": "Nanobiotix S.A: Behind The Recent Momentum",
    "summary": "Despite potential blockbuster royalties, NBTX's $1.1B stock valuation appears stretched due to limited pipeline and reliance on J&J for development. Read the full analysis here.",
    "url": "https://finnhub.io/api/news?id=0127b2e224e3f5a2e06d17c9ba056b5729805fc2de7402af0ef893528c008f4b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761215085,
      "headline": "Nanobiotix S.A: Behind The Recent Momentum",
      "id": 137196767,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1281832252/image_1281832252.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Despite potential blockbuster royalties, NBTX's $1.1B stock valuation appears stretched due to limited pipeline and reliance on J&J for development. Read the full analysis here.",
      "url": "https://finnhub.io/api/news?id=0127b2e224e3f5a2e06d17c9ba056b5729805fc2de7402af0ef893528c008f4b"
    }
  }
]